Onkologie. 2018:12(6):293-296 | DOI: 10.36290/xon.2018.053

Celiac disease – diangostics, therapy, risk of cancer

Barbora Packová, Michal Šenkyřík, Radek Kroupa
Interní gastroenterologická klinika FN Brno

Celiac disease is an immune-mediated small intestinal enteropathy, triggered by the ingestion of gluten in genetically predisposedindividuals. It's prevalence is about 1% in Europe. The symptoms are usually atypical in adulthood and the diagnostics comprisesof serology, gastroscopy with duodenal biopsy, possibly also genetic evaluation and intestinal ultrasonography. Gluten free dietis the only therapy. Development of refractory celiac disease must be taken in account in case of a persistence of symptoms inpatients adherent to gluten free diet. Associated malignant complications are rare but have severe prognosis.

Keywords: celiac disease, gluten free diet, refractory celiac disease, EALT

Published: December 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Packová B, Šenkyřík M, Kroupa R. Celiac disease – diangostics, therapy, risk of cancer. Onkologie. 2018;12(6):293-296. doi: 10.36290/xon.2018.053.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of CD in Europe: results of a centralized, international mass screening project. Ann Med. 2010; 42: 587-595. Go to original source... Go to PubMed...
    2. Spurkland A, Sollid LM, Polanco I, et al. HLA-DR and - DQ genotypes of celiac disease patients serologically typed to be non-DR3 or non-DR5/7. Hum Immunol. 1992; 35: 188-192. Go to original source... Go to PubMed...
    3. Molberg O, McAdam SN, Korner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med. 1998; 4: 713-717. Go to original source... Go to PubMed...
    4. Rostom A, Dube C, Cranney A, et al. The diagnostic accuracy of serologic tests for celiac disease: a systemic review. Gastroenterol. 2005; 128(1): 38-46. Go to original source... Go to PubMed...
    5. Prokešová J. Celiakie - staronová diagnóza. Reviz posud Lek. 2013; 16(3): 95-100.
    6. Sárdy M, Csikós M, Geisen C, et al. Tissue transglutaminase ELISA positivity in autoimmune disease independent of gluten-sensitive disease. Clinica Chimics Acta. 2007; 376: 126-135. Go to original source... Go to PubMed...
    7. Korponay-Szabo IR, Troncone R, Discepolo V, et al. Adaptive diagnosis of coeliac disease. Best Pract Res Cl Ga. 2015; 29: 381-398. Go to original source... Go to PubMed...
    8. Byrne G, Freeley M, Feighery C, et al. Protein kinase C delta is a substrate of tissue transglutaminase and a novel autoantigen in coeliac disease. Clin Imunol. 2013; 147(1): 1-8. Go to original source... Go to PubMed...
    9. Brown GJ, Daveson J, Marjason JK, et al. A phase 1 study to determine safety, tolerability and bioaktivity of Nexvax in HLA DQ2 + volunteers with celiac disease following a long-term, gluten-free diet. Gastroenterol. 2011; 140(5): 437-438. Go to original source...
    10. Siegel M, Garber ME, Spencer AG et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci. 2012; 57(2): 440-450. Go to original source... Go to PubMed...
    11. Sharkey LM, Corbett G, Currie E, et al. Optimising delivery of care in coeliac disease - comparison of the benefits of repeat biopsy and serological follow-up. Aliment PharmacolTher. 2013; 38: 1278-1291. Go to original source... Go to PubMed...
    12. Adrianse MPM, Tack GJ, Passos VL, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013; 37: 482-490. Go to original source... Go to PubMed...
    13. Marafini I, Di Sabatino A, Zorzi F, et al. Serum regenerating islet-derived 3-alpha is abiomarker of mucosal enteropathies. Alimentary Pharmacol Ther. 2014; 40(8): 974-981. Go to original source... Go to PubMed...
    14. Comino I, Real A, Vivas S et al. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces.Am J ClinNutr. 2012; 95(3): 670-677. Go to original source... Go to PubMed...
    15. Biagi F, Gobbi P, Marchesse A, et al. Low incidence but poor prognosis of complicated coeliac disease: A retrospective multicenter study. Dig Liver Dis. 2014; 46: 227-230. Go to original source... Go to PubMed...
    16. Malamut G, Cellier C. Refractory celiac disease: epidemiology and clinical manifestation. Dig Dis. 2015;33: 221-226. Go to original source... Go to PubMed...
    17. Patey-Mariaud De Serre N, Cellier C, Jabri B, et al. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology. 2000; 37: 70-77. Go to original source... Go to PubMed...
    18. Van Wanrooij RLJ, Muller DMJ, Neefjes-Borst EA, et al. Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractoty coeliac disease. J ClinImunol. 2014; 34: 828-835. Go to original source...
    19. Woodward J. The management of refractory coeliac disease.TherAdv Chronic Dis. 2013; 4(2): 77-90. Go to original source... Go to PubMed...
    20. Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognosticfactor. United European Gastroenterol J. 2017; 5(2): 208-217. Go to original source... Go to PubMed...
    21. Sieniawski M K, Lennard A L. Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies. Curr Hematol Malig Rep. 2011; 6: 231-240. Go to original source... Go to PubMed...
    22. Howdle PD, Jalal PK, Holmes GKT, et al. Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM. 2003; 96(5): 345-353. Go to original source... Go to PubMed...
    23. Benhammane H, El M'rabet F Z, Serhouchni KI, et al. Small Bowel Adenocarcinoma Complicating Coeliac Disease: A Report of Three Cases and the Literature Review. Case Reports in Oncological Medicine. 2012; doi:10.1155/2012/935183. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.